Interventional technology developer Boston Scientific has signed an agreement to purchase electrophysiology (EP) mapping and navigation firm Rhythmia Medical.
The price tag includes $90 million up front with additional payments through 2017 that could push the total value of the deal to $265 million.
Rhythmia's investigational mapping, navigation, and other technologies are used in cardiac catheter ablations and other interventional EP procedures for treating atrial fibrillation. The deal represents Boston Scientific's first foray into the EP and ablation market.
Next year the company expects to achieve a limited launch of the mapping system, which still lacks U.S. Food and Drug Administration (FDA) and CE Mark approval, with a full launch to follow in 2014, Boston Scientific said.
